Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin).
OBJECTIVE
To report a case of contralateral vitritis following intravitreal bevacizumab (Avastin, Roche Pharma).


METHODS
A 54-year-old man was treated with intravitreal bevacizumab (IB) for a choroidal neovascularization secondary to anisometropic high myopia in the right eye that did not respond to photodynamic treatment. After the second injection, he showed a moderate vitritis in the fellow un-injected eye a few hours later.


RESULTS
The patient was treated with a sub-Tenon's injection of 40 mg triamcinolone (Kenacort, Squibb) and entirely recovered his vision. No further complications were observed.


CONCLUSIONS
Although IB has a satisfactory safety profile, the possibility of unusual complications associated with the drug or the procedure itself should always be considered.
Neri
Piergiorgio
P
Neuroscience Department, Ophthalmology Section, Polytechnic University of Marche, Ancona, Italy. doctor_blacks@hotmail.com
Mariotti
Cesare
C
Mercanti
Lucia
L
Salvolini
Simone
S
Giovannini
Alfonso
A
D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005128:Eye Diseases / Q000139:chemically induced* / Q000175:diagnosis; D005451:Fluorescein Angiography; D007839:Functional Laterality; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body / Q000187:drug effects* / Q000473:pathology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab